33.21
price down icon2.09%   -0.71
after-market Dopo l'orario di chiusura: 33.21
loading
Precedente Chiudi:
$33.92
Aprire:
$33.84
Volume 24 ore:
916.60K
Relative Volume:
0.59
Capitalizzazione di mercato:
$4.00B
Reddito:
$10.12M
Utile/perdita netta:
$-280.49M
Rapporto P/E:
-11.49
EPS:
-2.89
Flusso di cassa netto:
$-188.51M
1 W Prestazione:
-2.44%
1M Prestazione:
+11.18%
6M Prestazione:
+11.93%
1 anno Prestazione:
-25.62%
Intervallo 1D:
Value
$33.10
$34.05
Intervallo di 1 settimana:
Value
$33.07
$35.14
Portata 52W:
Value
$21.51
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
Nome
Avidity Biosciences Inc
Name
Telefono
858-401-7900
Name
Indirizzo
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
Dipendente
391
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-07
Name
Ultimi documenti SEC
Name
RNA's Discussions on Twitter

Confronta RNA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RNA
Avidity Biosciences Inc
33.21 4.04B 10.12M -280.49M -188.51M -2.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-10 Ripresa Goldman Buy
2025-06-24 Iniziato Bernstein Outperform
2025-06-17 Iniziato Wolfe Research Outperform
2025-06-11 Iniziato Raymond James Strong Buy
2025-03-13 Iniziato Citigroup Buy
2025-03-12 Iniziato BMO Capital Markets Outperform
2025-03-07 Iniziato Scotiabank Sector Outperform
2024-12-20 Iniziato H.C. Wainwright Buy
2024-11-26 Iniziato RBC Capital Mkts Outperform
2024-09-24 Iniziato Goldman Buy
2024-08-28 Iniziato Barclays Overweight
2024-05-03 Iniziato BofA Securities Buy
2024-03-14 Iniziato Cantor Fitzgerald Overweight
2023-05-22 Aggiornamento Evercore ISI In-line → Outperform
2023-03-31 Downgrade Evercore ISI Outperform → In-line
2022-07-20 Iniziato Chardan Capital Markets Buy
2022-07-12 Iniziato Raymond James Strong Buy
2021-09-07 Iniziato Evercore ISI Outperform
2021-06-17 Iniziato Needham Buy
2021-04-26 Ripresa Credit Suisse Outperform
2020-07-07 Iniziato Cowen Outperform
2020-07-07 Iniziato Credit Suisse Outperform
2020-07-07 Iniziato SVB Leerink Outperform
2020-07-07 Iniziato Wells Fargo Overweight
Mostra tutto

Avidity Biosciences Inc Borsa (RNA) Ultime notizie

pulisher
Jul 24, 2025

How Avidity Biosciences Inc. stock reacts to Fed policy changesFree Smart Trading Workshop - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Is Avidity Biosciences Inc. a good long term investmentAccelerated wealth building - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Avidity Biosciences shares climb after FDA grants Breakthrough Therapy designation - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Avidity Biosciences shares rise 1.80% premarket after receiving FDA Breakthrough Therapy designation for DMD treatment. - AInvest

Jul 24, 2025
pulisher
Jul 24, 2025

What drives Avidity Biosciences Inc. stock priceOverwhelming profit margins - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

Avidity Biosciences Gains FDA Breakthrough Therapy Designation - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

Why Avidity Biosciences Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - beatles.ru

Jul 23, 2025
pulisher
Jul 23, 2025

Avidity gets FDA breakthrough therapy status for DMD treatment - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

FDA grants breakthrough therapy status to Avidity’s DMD drug By Investing.com - Investing.com Canada

Jul 23, 2025
pulisher
Jul 23, 2025

Avidity Biosciences stock rises after FDA grants Breakthrough Therapy status - Investing.com

Jul 23, 2025
pulisher
Jul 23, 2025

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - PR Newswire

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Avidity Biosciences Inc. stockOutstanding capital appreciation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Avidity Biosciences Inc. Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

(RNA) On The My Stocks Page - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 14, 2025

Avidity Biosciences: Three Accelerated Approval Shots Feels Excessive (NASDAQ:RNA) - Seeking Alpha

Jul 14, 2025
pulisher
Jul 14, 2025

RNA News Today | Why did Avidity Biosciences stock drop today? - MarketBeat

Jul 14, 2025
pulisher
Jul 10, 2025

Goldman Sachs resumes coverage on Avidity Biosciences stock with Buy rating - Investing.com Canada

Jul 10, 2025
pulisher
Jul 09, 2025

Avidity Biosciences, Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq

Jul 09, 2025
pulisher
Jul 09, 2025

Avidity Biosciences, Inc Rings the Opening Bell - Nasdaq

Jul 09, 2025
pulisher
Jul 07, 2025

Avidity Biosciences’ SWOT analysis: innovative muscle therapy stock faces key milestones - Investing.com

Jul 07, 2025
pulisher
Jun 30, 2025

Avidity Biosciences, Inc.(NasdaqGM: RNA) added to Russell 3000E Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 27, 2025

(RNA) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 27, 2025
pulisher
Jun 26, 2025

Avidity Biosciences’ Promising Phase 3 Study on FSHD Treatment: Market Implications - TipRanks

Jun 26, 2025
pulisher
Jun 18, 2025

Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027 - Investing.com

Jun 18, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on Avidity Biosciences (RNA) with 'Outperform' Rating | RNA Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotec - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotech Advancements | RNA Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

(RNA) Proactive Strategies - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Avidity Biosciences (RNA) Receives Outperform Rating from Wolfe Research | RNA Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 15, 2025

The week in pharma: action, reaction and insight – week to June 13 - The Pharma Letter

Jun 15, 2025
pulisher
Jun 14, 2025

Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential - Investing.com Australia

Jun 14, 2025
pulisher
Jun 14, 2025

Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential By Investing.com - Investing.com South Africa

Jun 14, 2025
pulisher
Jun 13, 2025

Avidity Biosciences chief scientific officer sells $657,694 in stock - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Avidity Biosciences chief scientific officer sells $657,694 in stock By Investing.com - Investing.com South Africa

Jun 12, 2025

Avidity Biosciences Inc Azioni (RNA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):